EverSource Wealth Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

EverSource Wealth Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$16.3K	Buy	1,294 +146	+13%	+$1.96K	﹤0.01%	2631
2025 Q4	$18.1K	Hold	1,148	–	–	﹤0.01%	2451
2025 Q3	$13.7K	Sell	1,148 -5	-0.4%	-$40	﹤0.01%	2628
2025 Q2	$8.72K	Buy	1,153 +1,013	+724%	+$6.09K	﹤0.01%	2889
2025 Q1	$773	Buy	140 +110	+367%	+$679	﹤0.01%	3321
2024 Q4	$173	Buy	+30	New	+$288	﹤0.01%	3455
2023 Q3	–	Sell	-68	Closed	-$1.46K	–	2551
2023 Q2	$1.46K	Buy	+68	New	+$2K	﹤0.01%	2108
2022 Q2	–	Sell	-38	Closed	-$3K	–	1760
2022 Q1	$3K	Hold	38	–	–	﹤0.01%	1408
2021 Q4	$3K	Buy	+38	New	+$2.98K	﹤0.01%	1411

Other funds holding ENTA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

SSC

Spruce Street Capital New York $416M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

EverSource Wealth Advisors's ENTA Position: Q1 2026 in Review

EverSource Wealth Advisors increased its Enanta Pharmaceuticals (ENTA) stake by 13% in Q1 2026, buying an estimated $1.96K and bringing the position to 1,294 shares worth $16.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2631.

EverSource Wealth Advisors first reported a position in ENTA in Q4 2021 and has held it in 9 quarters since. The position peaked at $18.1K in Q4 2025. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

EverSource Wealth Advisors held 1,294 shares of Enanta Pharmaceuticals worth $16.3K as of Q1 2026.
EverSource Wealth Advisors bought 146 Enanta Pharmaceuticals shares in Q1 2026, an estimated $1.96K.
Enanta Pharmaceuticals made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q1 2026, its #2631 holding.
EverSource Wealth Advisors first reported a position in Enanta Pharmaceuticals in Q4 2021 and has held it in 9 quarters since.
EverSource Wealth Advisors's Enanta Pharmaceuticals position peaked at $18.1K in Q4 2025.
132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.